Osteoarthritis Clinical Trials

Find Osteoarthritis Clinical Trials Near You

The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip Replacement

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this randomised controlled trial is to compare the success of two types of hip replacement in patients with hip arthritis. The main question it aims to answer is whether a new type of hip replacement (called a hip resurfacing) can be as successful as an existing hip replacement (called a total hip replacement). Patients will be given either the new hip resurfacing or the existing total hip replacement and researchers will compare their function, complication rate and physical activity.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patient requires unilateral primary hip arthroplasty due to primary osteoarthritis, osteoarthritis secondary to e.g. trauma, avascular necrosis or developmental hip dysplasia, or inflammatory arthritis.

• Patient is willing to comply with study requirements.

• Patient plans to be available through 10 years postoperative follow-up.

Locations
Other Locations
United Kingdom
University Hospitals Dorset NHS Foundation Trust
RECRUITING
Bournemouth
University Hospitals Coventry & Warwickshire
RECRUITING
Coventry
Royal Cornwall Hospitals NHS Trust
RECRUITING
Truro
Contact Information
Primary
Camilla Halewood, PhD
camilla.halewood@embody-ortho.com
+442035764981
Backup
Susannah Clarke, PhD
susannah.clarke@embody-ortho.com
+442035764981
Time Frame
Start Date: 2026-07-21
Estimated Completion Date: 2036-12-31
Participants
Target number of participants: 200
Treatments
Experimental: The H1 Implant
Cementless, ceramic-on-ceramic hip resurfacing arthroplasty (HRA) device.
Active_comparator: Cementless total hip replacement
Cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
Sponsors
Leads: Embody Orthopaedic Limited
Collaborators: Imperial College London, National Institute for Health Research, United Kingdom

This content was sourced from clinicaltrials.gov